RSCM
MIRM icon

Rock Springs Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Rock Springs Capital Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.9M Buy
811,294
+49,000
+6% +$4.61M 4.42% 4
2025
Q4 		$60.2M Buy
762,294
+1,168
+0.2% +$83.8K 3.09% 8
2025
Q3 		$55.8M Sell
761,126
-57,080
-7% -$3.63M 3.26% 7
2025
Q2 		$41.6M Sell
818,206
-133,559
-14% -$5.95M 2.59% 10
2025
Q1 		$42.9M Sell
951,765
-519,799
-35% -$24.5M 2.45% 12
2024
Q4 		$60.8M Sell
1,471,564
-108,924
-7% -$4.54M 2.32% 11
2024
Q3 		$61.6M Sell
1,580,488
-191,550
-11% -$7.64M 2.01% 12
2024
Q2 		$60.6M Sell
1,772,038
-84,526
-5% -$2.22M 1.82% 14
2024
Q1 		$46.6M Buy
1,856,564
+5,100
+0.3% +$140K 1.18% 31
2023
Q4 		$54.7M Buy
1,851,464
+30,731
+2% +$930K 1.35% 24
2023
Q3 		$57.5M Hold
1,820,733
– – 1.54% 22
2023
Q2 		$47.1M Buy
1,820,733
+25,000
+1% +$665K 1.12% 30
2023
Q1 		$43.1M Hold
1,795,733
– – 1.03% 32
2022
Q4 		$35M Hold
1,795,733
– – 0.84% 42
2022
Q3 		$37.7M Buy
1,795,733
+78,000
+5% +$1.88M 0.97% 38
2022
Q2 		$33.4M Buy
1,717,733
+51,525
+3% +$1.22M 0.97% 36
2022
Q1 		$36.7M Buy
1,666,208
+127,394
+8% +$2.6M 0.92% 37
2021
Q4 		$24.5M Buy
1,538,814
+13,191
+0.9% +$205K 0.57% 56
2021
Q3 		$30.4M Buy
1,525,623
+1,900
+0.1% +$30.9K 0.64% 51
2021
Q2 		$26.3M Buy
1,523,723
+20,923
+1% +$375K 0.52% 58
2021
Q1 		$29.8M Buy
1,502,800
+6,275
+0.4% +$120K 0.65% 53
2020
Q4 		$26.1M Buy
1,496,525
+168,911
+13% +$3.32M 0.55% 60
2020
Q3 		$25.6M Buy
1,327,614
+7,704
+0.6% +$165K 0.65% 52
2020
Q2 		$25.7M Buy
1,319,910
+76,910
+6% +$1.29M 0.7% 53
2020
Q1 		$17.4M Sell
1,243,000
-2,000
-0.2% -$32.8K 0.72% 49
2019
Q4 		$30.5M Buy
1,245,000
+454,952
+58% +$4.85M 0.96% 39
2019
Q3 		$7.95M Buy
+790,048
New +$9.69M 0.32% 84

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Rock Springs Capital Management's MIRM Position: Q1 2026 in Review

Rock Springs Capital Management increased its Mirum Pharmaceuticals (MIRM) stake by 6.4% in Q1 2026, buying an estimated $4.61M and bringing the position to 811,294 shares worth $74.9M. The position accounts for 4.42% of the portfolio, ranked #4.

Rock Springs Capital Management first reported a position in MIRM in Q3 2019 and has held it in 27 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Rock Springs Capital Management held 811,294 shares of Mirum Pharmaceuticals worth $74.9M as of Q1 2026.
  • Rock Springs Capital Management bought 49,000 Mirum Pharmaceuticals shares in Q1 2026, an estimated $4.61M.
  • Mirum Pharmaceuticals made up 4.42% of Rock Springs Capital Management's portfolio in Q1 2026, its #4 holding.
  • Rock Springs Capital Management first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 27 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.